UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance

Abstract

Ubiquitin carboxyl terminal hydrolase 1 (UCHL1) catalyzes the hydrolysis of COOH-terminal ubiquityl esters and amides. It has been reported as either an oncogene or a tumor suppressor in cancers. However, UCHL1's role in ovarian cancer is still unclear. Therefore, we conducted an analysis to understand the role of UCHL1 in ovarian cancer. Firstly, we detected UCHL1 promoter methylation status in 7 ovarian cancer cell lines. 4 of them with UCHL1 silencing showed heavy promoter methylation while the other 3 with relative high UCHL1 expression showed little promoter methylation. Then we reduced UCHL1 expression in ovarian cancer cell line A2780 and IGROV1 and found that inhibition of UCHL1 promoted cell proliferation by increasing cells in S phases of cell cycle. Knockdown of UCHL1 also reduced cell apoptosis and contributed to cisplatin resistance. Furthermore, the expression level of UCHL1 in several ovarian cancer cell lines correlated negatively with their cisplatin resistance levels. Microarray data revealed that UCHL1 related genes are enriched in apoptosis and cell death gene ontology (GO) terms. Several apoptosis related genes were increased after UCHL1 knockdown, including apoptosis regulator BCL2, BCL11A, AEN and XIAP. Furthermore, we identified up-regulation of Bcl-2 and pAKT as well as down-regulation of Bax in UCHL1 knockdown cells, while no significant alteration of p53 and AKT1 was found. This study provides a new and promising strategy to overcome cisplatin resistance in ovarian cancer via UCHL1 mediated pathways.

Proteomic analysis of β-asarone induced cytotoxicity in human glioblastoma U251 cells

“…On the other hand, promoter hypermethylation leading to silencing of UCHL1 has been reported in progression of prostate cancer [22], breast cancer [23], nasopharyngeal carcinoma [24], hepatocellular carcinoma and other digestive tumors [25]. In ovarian cancer cells, UCHL1 is also reported to be a tumor suppressor and knockdown of UCHL1 contributes to cisplatin resistance [26]. UCH-L1 is up-regulated by ␤-asarone in the current study.…”

Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis

“…Interestingly, none had been implicated in AGL biology or function. Ubiquitin carboxyl-terminal esterase L1 (UCHL1) and semaphorin 3A (SEMA3A) have been shown to be tumor suppressors in other tumor models (10–13) hence were not investigated further here.…”

UCH‐L1 promotes invasion of breast cancer cells through activating Akt signaling pathway

“…As a de-ubiquitination enzyme, UCH-L1 is considered as a tumor promoting protein in many human tumors. [16][17][18][19][20][21][22][23][24] However, the function of UCH-L1 in tumor initiation, progression and invasion is still controversial, as UCH-L1 has also been found to be downregulated in other tumor types including prostate cancer, 47 ovarian cancer, 48 and nasopharyngeal cancer. 49 Therefore, the potential role of UCH-L1 as an oncogene or a tumor suppressor may be cell context or tissue specific.…”